22nd Century Group (Nasdaq: XXII) to Participate in A.G.P./Alliance Global Partner’s Virtual Spring Consumer Cannabis Conference

Rhea-AI Summary

22nd Century Group, Inc. (Nasdaq: XXII), an agricultural biotechnology company, will host virtual meetings with investors at the A.G.P./Alliance Global Partners Spring Consumer Cannabis Conference on May 3, 2022. CEO James A. Mish and CFO Richard Fitzgerald will represent the company. Institutional investors can schedule meetings through their Alliance Global Partners contact or by reaching out to the investor relations team. 22nd Century focuses on tobacco harm reduction through reduced nicotine tobacco and holds patents for nicotine biosynthesis control. The company received FDA authorization for a reduced nicotine cigarette in December 2021.

BUFFALO, N.Y., April 27, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through modern plant science, today announced that James A. Mish, Chief Executive Officer, and Richard Fitzgerald, Chief Financial Officer, will host virtual meetings with investors at the A.G.P./Alliance Global Partners Spring Consumer Cannabis Conference on Tuesday, May 3, 2022.

Institutional investors participating in the conference can request a meeting with management through their Alliance Global Partners representative, or by contacting 22nd Century Group’s investor relations team via investorrelations@xxiicentury.com.

About 22nd Century Group, Inc.
22nd Century Group, Inc. (Nasdaq: XXII) is a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science. With dozens of patents allowing it to control nicotine biosynthesis in the tobacco plant, the Company has developed proprietary reduced nicotine content (RNC) tobacco plants and cigarettes, which have become the cornerstone of the FDA’s Comprehensive Plan to address the widespread death and disease caused by smoking. The Company received the first and only FDA MRTP authorization of a combustible cigarette in December 2021. In tobacco, hemp/cannabis, and hop plants, 22nd Century uses modern plant breeding technologies, including genetic engineering, gene-editing, and molecular breeding to deliver solutions for the life science and consumer products industries by creating new, proprietary plants with optimized alkaloid and flavonoid profiles as well as improved yields and valuable agronomic traits.

Learn more at xxiicentury.com, on Twitter, on LinkedIn, and on YouTube.

Cautionary Note Regarding Forward-Looking Statements
Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking statements typically contain terms such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “explore,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in “Risk Factors” in the Company’s Annual Report on Form 10-K filed on March 11, 2021. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

Investor Relations & Media Contact:
Mei Kuo
22nd Century Group, Inc.
Director, Communications & Investor Relations
T: 716-300-1221
mkuo@xxiicentury.com

Darrow Associates Investor Relations
Matt Kreps
T: 214-597-8200
mkreps@darrowir.com

FAQ

What is the date of the A.G.P./Alliance Global Partners Spring Consumer Cannabis Conference for XXII?

The A.G.P./Alliance Global Partners Spring Consumer Cannabis Conference for 22nd Century Group, Inc. (XXII) is on May 3, 2022.

Who will represent XXII at the Spring Consumer Cannabis Conference?

CEO James A. Mish and CFO Richard Fitzgerald will represent 22nd Century Group, Inc. (XXII) at the conference.

How can institutional investors meet with XXII management at the conference?

Institutional investors can schedule meetings with XXII management through their Alliance Global Partners representative or contact the investor relations team.

What is the focus of 22nd Century Group, Inc. (XXII)?

22nd Century Group, Inc. (XXII) focuses on tobacco harm reduction and modern plant science to improve health and wellness.

What significant FDA authorization did XXII receive?

22nd Century Group, Inc. (XXII) received the first and only FDA Modified Risk Tobacco Product (MRTP) authorization for a combustible cigarette in December 2021.